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oan Brugge was an undergraduate at 
Northwestern University when her 
sister was diagnosed with a brain 
tumor. Her sister’s doctors couldn’t say 
what caused the disease; they speculated 
that a virus might be involved. This 
spurred Brugge’s lifelong quest to learn 
about the causes of cancer, starting with 
the study of tumor viruses (1).
Brugge identifi  ed the protein encoded 
by the src transforming gene of Rous sar-
coma virus and its cellular homologue as 
a postdoc in Ray Erikson’s lab at the Uni-
versity of Colorado (2). She further char-
acterized the cellular Src protein during 
her time as a group leader at Stonybrook 
and the University of Pennsylvania (3). 
Later, following a brief stint in the private 
sector, she set up shop at Harvard Medical 
School to study the cellular processes that 
drive the striking morphological and pheno-
typic changes that accompany cancerous 
transformation in humans (4–6).
A leader in the fi  eld of cancer biology, 
Brugge manages a vibrant research pro-
gram while meeting the demands of chair-
ing the Department of Cell Biology. But, 
she took time out to chat with us about her 
career—past, present, and future.
STARTING LINE
When you ﬁ  rst started working on cancer, 
what did people think caused the disease?
At the time, the causes of human cancer 
were elusive. There were only a few in-
ducible tumor virus mod-
els available besides those 
using chemical carcinogens. 
There were a few “RNA 
tumor virus” models in 
chickens and mice as well 
as some DNA tumor viruses, 
with SV40 as a prototype. 
As a graduate student, I 
worked on the tumor anti-
gen of SV40. It was very diffi  cult to study 
the mechanisms of transformation because 
SV40 transformation was ineffi  cient 
and slow; while SV40 tumor antigen is 
required to maintain the transformed state, 
additional hits are required in order to 
induce transformation. So, as a postdoc I 
switched to studying Rous sarcoma virus 
(RSV), which could transform cells in 
just two days. It seemed clear that the 
viral gene product—which by that time 
was known to be Src—could transform 
cells on its own. Shortly after I started my 
postdoc in 1975, Harold Varmus, Michael 
Bishop, and colleagues identifi  ed the viral 
Src gene of RSV as an adopted and dysreg-
ulated cellular gene.
We and many other labs around the 
country were trying to identify the cellu-
lar Src protein. We spent two years trying 
endless approaches to do it. I was almost 
at the point of giving up when we fi  nally 
detected it on a gel! Then another postdoc 
in the lab, Marc Collette, identifi  ed Src as 
a protein kinase (in parallel with Art 
Levinson in Mike Bishop’s and Harold 
Varmus’ lab). That provided a major clue 
as to the nature of cellular activities that 
could contribute to transformation.
CHICANE FOR CANCER
How did the discovery of c-Src change 
your thoughts about cancer?
If you follow the papers from when I fi  rst 
started my own lab, we set out on an un-
charted path pursuing the cellular func-
tions of Src. There was an assumption that 
it was going to be involved in regulating 
normal cell proliferation, and that the vi-
rus’ mutated version would 
constitutively stimulate cell 
proliferation. But, we gained 
a much broader view of Src 
over time when we realized 
that it is activated by many 
receptors and controls many 
different cellular proteins. 
This is one of many exam-
ples of how nature is very 
conservative in its use of proteins. Other 
key regulatory proteins associated with tu-
mor viruses—Ras, Myc, Fos—were also 
found to regulate a really wide assortment 
of cellular activities controlled by diverse 
receptors. Scientists typically focused on 
the products of individual proto-oncogenes, 
and in the process discovered that these pro-
teins regulate activities that go well beyond 
cell proliferation. That led to the realization 
that tumor development involves the dys-
regulation of multiple cellular functions 
besides just proliferation—things like adhe-
sion, polarity, metabolism, and apoptosis.
What guides your thinking about 
cancer today?
For the past several years my lab at Harvard 
has been trying to understand what cellular 
processes and pathways are responsible for 
the really signifi  cant changes in the organi-
zation of normal tissues that are associated 
with cancer. For instance, the glandular 
unit of the breast, the acinus, is a hollow 
sphere. In breast cancer, tumors demon-
strate a whole spectrum of architectural 
changes in this structure: the spheres can 
be hollow or fi  lled with cells; they can 
lose cellular polarity, or not; they can be 
invasive, or not. We’ve been working on 
understanding the processes that drive 
these different phenotypic histologies, 
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using a breast cancer model system we 
adapted from Mina Bissell’s 3D cell cul-
ture work.
Most recently, we’ve been studying the 
mechanisms that are responsible for the 
ability of tumor cells to survive without 
attachment to the extracellular matrix. Our 
3D model system had shown us that acini 
start out as a solid sphere of cells. The hol-
low lumen is generated during morphogen-
esis through selective apoptosis of the inner 
cells. But we noticed that if you blocked 
apoptosis in these cells, they still died.
Many lines of evidence from our 
laboratory supported the idea that the 
cells in the center are stressed by loss of 
attachment to matrix. We found that 
matrix detachment was associated with 
a block in glucose uptake that causes a 
dramatic drop in cellular ATP levels. 
And then we got this really surprising 
result: we could rescue the ATP levels 
and prevent cell death if we added anti-
oxidants. We found that antioxidants 
allow the use of an alternate energy path-
way, fatty acid oxidation. Antioxidants 
are up-regulated in a reasonable number 
of tumors, so now we’d like to under-
stand to what extent they might actually 
contribute to tumor progression.
CLEARING HURDLES
What are the major hurdles you’ve faced 
in your career?
Just deciding to pursue research as a 
career was one hurdle. When I was in 
high school, the women who had careers 
around me were either nurses or teachers. 
I loved problem solving and was good at 
math, so I thought I might be a high 
school math teacher. Later on, when I 
decided to go to graduate school, I didn’t 
have a lot of guidance because a research 
career wasn’t a common choice. I picked 
my graduate school, Baylor College of 
Medicine, out of a Peterson’s Guide. 
[laughs] Undergraduates are so much 
more sophisticated today.
Later, as a graduate student, I had 
decided that I could not handle an inde-
pendent faculty position and have a family 
as well; so I planned to be a research 
associate in someone else’s lab. So, one of 
my largest hurdles happened after my son 
Shawn was born, when I was a postdoc at 
the University of Colorado. It was really 
emotionally diffi  cult for me to go back to 
work. I was very reluctant to leave his 
care to anyone else. However, I was also 
excited to get back to my studies of the 
Src protein, which we’d fi  nally discovered 
just a few months before 
Shawn was born. It took a 
few tries before I eventually 
found some wonderful peo-
ple I felt I could trust to 
help care for him in a warm 
and loving environment. 
That really helped me suc-
ceed in my career, but it 
wasn’t effortless. My post-
docs know I appreciate the 
challenges of trying to bal-
ance a career in science 
with the demands of parent-
hood. Both my husband and my son have 
been incredibly supportive of me in my 
career, so having a family is not some-
thing I take for granted.
Do you have advice for young scientists?
One thing I think is important for young 
scientists to know is that you really 
can’t predict what your potential is 
going to be. Too often I hear post-
docs and junior faculty—especially 
women—say, “I could never handle 
doing what you’re doing.” They’re 
afraid they won’t be able to balance 
having a career with the demands of 
having a family. Or, maybe they just 
feel overwhelmed when they look 
at the breadth of responsibilities 
that senior faculty have to manage. 
But it’s important to understand that you 
don’t have to tackle those kinds of respon-
sibilities right away. You will take on new 
responsibilities as your career evolves and 
you gather the resources to handle them; 
you don’t have to do it all at once.
My message to junior 
faculty and postdocs, then, is 
that it’s important to take 
baby steps in your career. At 
each step, assess whether 
you feel comfortable and 
whether you still enjoy what 
you’re doing. Don’t make 
assumptions about what 
your capabilities are. Just 
try it and see how it goes.
Also, when it comes to 
your experiments, don’t be 
afraid to chase down a 
strange result. Recently, a postdoc in my 
lab, Michael Overholtzer, made a puzzling 
observation that he decided to investigate. 
In the process, he discovered a phenome-
non we called entosis—when cells inter-
nalize into neighboring cells—that could 
be involved in either preventing or promot-
ing cancer. He’s now investigating that in 
his own lab. So remember that when some-
thing unexpected happens, it might shine a 
light in the black box of biology.
1. Brugge, J.S., and J.S. Butel. 1975. J. Virol. 
15:619–635.
2. Brugge, J.S., and R.L. Erikson. 1977. Nature. 
269:346–348.
3. Lynch, S.A., et al. 1986. Science. 234:873–876.
4. Debnath, J., et al. 2002. Cell. 111:29–40.
5. Overholtzer, M., et al. 2007. Cell. 131:966–979.
6. Schafer, Z.T., et al. 2009. Nature. 461:109–113.
A breast cancer cell line forms hollow spheres 






a light in the 
black box of 
biology.”
The extended family of the Brugge lab.